Literature DB >> 760018

Estrogen and progestin binding in cytosols of ovarian adenocarcinomas.

J A Holt, T A Caputo, K M Kelly, P Greenwald, S Chorost.   

Abstract

Because a few ovarian adenocarcinomas respond favorably to endocrine therapy, we tested the hypothesis that some ovarian adenocarcinomas have functional similarity with sex-hormone-sensitive endometrial and breast tumors. Cytosols from 23 ovarian adenocarcinomas and 27 control tissues were examined for receptorlike estrogen and/or progestin binding. Eight of 16 primary ovarian adenocarcinomas had estrogen and/or progestin receptorlike components; among the metastases tested, one third retained estrogen binding. No correlations were found between binding characteristics and histopathologic grade. The presence of estrogen binding in a lung lesion helped confirm recurrent ovarian disease. Estrogen binding occurred in specimens from women with no histories of exposure to exogenous estrogen. Because tamoxifen and nafoxidine could inhibit estradiol binding, it is likely that antiestrogens will prove beneficial against some ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 760018

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

1.  Hormonal aspects of ovarian malignancy.

Authors:  J Waxman
Journal:  J R Soc Med       Date:  1984-03       Impact factor: 5.344

2.  Immunocytochemical staining of progesterone receptor in paraffin sections of human breast cancers.

Authors:  M Perrot-Applanat; M T Groyer-Picard; M T Vu Hai; C Pallud; F Spyratos; E Milgrom
Journal:  Am J Pathol       Date:  1989-09       Impact factor: 4.307

Review 3.  Tamoxifen for relapse of ovarian cancer.

Authors:  Chris Williams; Iveta Simera; Andrew Bryant
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

4.  Simultaneous occurrence of receptors for estradiol, progesterone, and dihydrotestosterone in canine mammary tumors.

Authors:  H Elling; F R Ungemach
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

Review 5.  The predictive value of steroid hormone receptor analysis in breast, endometrial and ovarian cancer.

Authors:  R Vihko; A Alanko; V Isomaa; A Kauppila
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

6.  Dietary factors and epithelial ovarian cancer.

Authors:  X O Shu; Y T Gao; J M Yuan; R G Ziegler; L A Brinton
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

7.  Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule.

Authors:  R J Osborne; S T Malik; M L Slevin; V J Harvey; J Spona; H Salzer; C J Williams
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640

8.  The clinical activity of cyproterone acetate in advanced ovarian carcinoma. A London Gynaecology Oncology Group Study.

Authors:  P Thompson; P Wilson; R Osborne; M Slevin; F Wiltshaw; P Blake; P Harper; R Coleman; C Williams; J Sweetenham
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.